Transgene et al. vs Replimune Limited

Final Written Decision: original

Other: Hearing transcript

ORDER Conduct of the Proceeding 37 C.F.R. § 42.5

Petitioners Additional Briefing Regarding Xerox and Intel

Patent Owner's Supplemental Brief Regarding Xerox and Intel

ORDER Conduct of the Proceeding 37 C.F.R. sec 42.5

Exhibit 1107 - Petitioners' Demonstrative Exhibits

Exhibit 2024 - Patent Owner's Demonstrative Exhibits

LEAP Practitioner Request and Verification Form (Patent Owner)

Petitioners Unopposed Motion for Refund of Fees

Order: Setting Oral Argument

Petitioners' Request for Refund

Petitioners' Request for Oral Argument

Patent Owner's Request for Oral Argument

Patent Owner Sur-Reply

Petitioners' Reply PGR2022-00014

Petitioners' Exhibit List as of December 20, 2022

Ex 1101 Guo et al 2017

Ex 1102 Guse et al 2010

Ex 1103 Rintoul et al 2011

Ex 1104 Chiocca Deposition Notice

Ex 1105 Yamamoto et al 2006

Ex 1106 Chiocca Deposition Transcript with Errata

Notice of Deposition of E. Antonio Chiocca M.D., Ph.D.

Patent Owner Response

EX2008 - US20220056480A1

EX2009 - Declaration of E. Antonio Chiocca

EX2010 - Semmrich Poster

EX2011 - Semmrich 2022

EX2012 - Zitvogel PH Excerpt

EX2013 - Thomas

EX2014 - Kaufman 2015

EX2015 - Silvestre PH Excerpt

EX2016 - 513 PH (4-30-2020 Response)

EX2017 - Rojas 2015

EX2019 - Yang

EX2020 - Kleinpeter 2016

EX2021 - Transcript of John C. Bell

EX2022 - Lun 2009

EX2023 - Chiocca E. Antonio CV

Patent Owner's Notice of Deposition of John C. Bell

Notice of Joint Stipulation to Modify Schedule

Patent Owner's Objections to Evidence

Petitioners' Updated Mandatory Notices as of June 22, 2022

Institution Decision: Grant

Order: SCHEDULING ORDER

Order: Panel Change Order

Patent Owner's List of Improper Preliminary Reply Arguments

Exhibit 2007 - Email dated 19 April 2022 from Board to A. Stein

Patent Owner's Updated Exhibit List

Petitioners' Reply to Patent Owner's Preliminary Response

Patent Owners Updated Exhibit List

Exhibit 2006 - Rough Transcript of 6 April 2022 Conference Call with the Board

ERRATUM

ORDER Conduct of the Proceeding Granting-In-Part Petitioners Request to File a Pre-Institution Reply 37 C.F.R. sec 42.5

Patent Owner's Preliminary Response

Exhibit 2001 - Disclaimer

Exhibit 2002 - Jan 13, 2021 Examiner Interview Summary

Exhibit 2003 - Jan 29, 2021 Applicant Interview Summary

Exhibit 2004 - Feb 1, 2021 Notice of Allowance

Exhibit 2005 - Third Party Observations

Patent Owner Replimune Limited's Mandatory Notice

Patent Owner Replimune Limited's Power of Attorney

Notice: Notice filing date accorded

Petition for Post-Grant Review of U.S. Patent No. 10,947,513

Transgene Power of Attorney

BioInvent International AB Power of Attorney

Petitioner's Exhibit List as of December 15, 2021

U.S. Patent No. 10,947,513

U.S. Patent No. 10,555,981

Du et al., Tumor-specific oncolytic adenoviruses expressing granulocyte macrophage colony-stimulating factor or anti-CTLA4 antibody for the treatment of cancers, 21 CANCER GENE THERAPY 340-348 (2014)

U.S. Patent No. 10,765,710

Choi et al., Concurrent delivery of GM-CSF and B7-1 using an oncolytic adenovirus elicits potent antitumor effect, 13 GENE THERAPY 1010-1020 (2006)

Curriculum vitae of John C. Bell, Ph.D.

Declaration of John C. Bell, Ph.D. dated December 14, 2021

British Patent Application GB 1600380

British Patent Application GB 1600381

British Patent Application GB 1600382

Declaration of Dr. Sylvia D. Hall-Ellis dated November 29, 2021

Curriculum vitae of Dr. Sylvia D. Hall-Ellis

International Patent Application PCT/GB2017/050038

Published International Patent Application WO 2017/118866

Kaufman et al., Oncolytic viruses: a new class of immunotherapy drugs, 14 CANCER IMMUNOTHERAPY 642-662 (September 2015)

Amendment filed on February 26, 2020 in U.S. Patent Application Serial No. 16/068,830

Notice of Allowance mailed on November 3, 2020, in U.S. Patent Application Serial No. 16/068,830 with attached Interview Summary

Information Disclosure Statement filed on October 16, 2018, in U.S. Patent Application Serial No. 16/068,830

Notice of Allowance mailed on December 23, 2020, in U.S. Patent Application Serial No. 16/068,830 with attached PTO forms PTO-1449

Notice of Allowance mailed on December 29, 2020, in U.S. Patent Application Serial No. 16/068,830 with attached PTO forms PTO-1449

Excerpts from S. Baron (Ed.), MEDICAL MICROBIOLOGY, 4th. Ed., University of Texas Medical Branch at Galveston (1996)

Species list extracted from International Committee on Taxonomy of Viruses (ICTV) Master Species List (July 20, 2021), available at https://talk.ictvonline.org/taxonomy/vmr/

Output from the National Institutes of Health (NIH) National Center for Biotechnology Information (NCBI) Taxonomy Browser searches for select viruses (performed Nov. 3, 2021), available at https://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Root

List of known isolates within each virus family extracted from NCBI Taxonomy Browser Output of Ex. 1023

Herpesviridae Information from Virus Pathogen Resource (ViPR) retrieved on Nov. 4, 2021, available at https://www.viprbrc.org/brc/aboutPathogen.spg?decorator=herpes

Oliveira et al., Poxvirus Host Range Genes and Virus-Host Spectrum: A Critical Review, 9(11) VIRUSES 2017 331 (Nov. 7, 2017)

Saha et al., The Adenovirus Genome Contributes to the Structural Stability of the Virion, 6(9) VIRUSES 2014 3563-3583 (Sep. 24, 2014)

Balvay et al., Translational control of retroviruses, 5 NATURE REVIEWS MICROBIOLOGY 128-140 (Feb. 2007)

Compilation of Virus Information from Swiss Institute of Bioinformatics retrieved on Nov. 3, 2021, available at https://viralzone.expasy.org/

Reoviridae Information from Virus Pathogen Resource (ViPR) retrieved on Nov. 4, 2021, available at https://www.viprbrc.org/brc/aboutPathogen.spg?decorator=reo

Summary of Characteristics of Commercial Viral Vectors

van den Wollenberg et al., Replicating reoviruses with a transgene replacing the codons for the head domain of the viral spike, 22 GENE THERAPY 267-279 (2015)

Majid et al., Recombinant Vesicular Stomatitis Virus (VSV) and Other Strategies in HCV Vaccine Designs and Immunotherapy. Tan SL, (Ed.) HEPATITIS C VIRUSES: GENOMES AND MOLECULAR BIOLOGY, Ch. 15. Norfolk (UK): Horizon Bioscience (2006)

Jacobs et al., HSV-1 based vectors for gene therapy of neurological diseases and brain tumors Part II Vector Systems and Applications, 1(5) NEOPLASIA 402-416 (November 1999)

Ho et al., Unconventional viral gene expression mechanisms as therapeutic targets, 593 NATURE 362-371 (May 2021)

Salzberg, Open questions: How many genes do we have? 16 BMC BIOLOGY 94 (August 20, 2018)

Hillier et al., Genomics in C. elegans: so many genes, such a little worm, 15 GENOME RESEARCH 1651-60 (2005)

Lundstrom, New frontiers in oncolytic viruses: optimizing and selecting for virus strains with improved efficacy, 12 BIOLOGICS: TARGETS AND THERAPY 43-60 (2018)

Liu et al., ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties, 10 GENE THERAPY 292-303 (2003)

Ma et al., Oncolytic herpes simplex virus and immunotherapy, 19 BMC IMMUNOLOGY 40 (2018)

Singh et al., Oncolytic viruses & their specific targeting to tumour cells, 136 INDIAN J. MED. RES. 571-584 (October 2012)

Yang et al., Cascade regulation of vaccinia virus gene expression is modulated by multistage promoters, 447(1-2) VIROLOGY 213-220 (December 2013)

Riedel et al., Components and Architecture of the Rhabdovirus Ribonucleoprotein Complex, 12(9) VIRUSES 2020 959 (August 2020)

Dikstein, The unexpected traits associated with core promoter elements, 2(5) TRANSCRIPTION 201-206 (September 2011)

Willemsen and Zwart, On the stability of sequences inserted into viral genomes, 5(2) VIRUS EVOLUTION vez045 (July 2019)

Brochu-Lafontaine and Lemay, Addition of exogenous polypeptides on the mammalian reovirus outer capsid using reverse genetics, 179 J. VIROL. METHODS 342-350 (2012)

Belsham and Sonenberg, RNA-protein interactions in regulation of picornavirus RNA translation, 60(3) MICROBIOLOGICAL REVIEWS 499-511 (September 1996)

Donovan-Banfield et al., Deep splicing plasticity of the human adenovirus type 5 transcriptome drives virus evolution, 3 COMMUNICATIONS BIOLOGY (2020) 124

Yen et al., Vaccinia virus infection & temporal analysis of virus gene expression: Part 2, 2009(26) J. VIS. EXP. 1169 (April 2009)

Wertz et al., Adding genes to the RNA genome of vesicular stomatitis virus: positional effects on stability of expression, 76(15) J. VIROL. 7642-50 (August 2002)

Bett et al., Packaging capacity and stability of human adenovirus type 5 vectors, 67(10) J. VIROL. 5911-21 (October 1993)

Malhotra et al., Use of an Oncolytic Virus Secreting GM-CSF as Combined Oncolytic and Immunotherapy for Treatment of Colorectal and Hepatic Adenocarcinomas, 141(4) SURGERY 520-529 (April 2007)

Engeland et al., CTLA-4 and PD-L1 Checkpoint Blockade Enhances Oncolytic Measles Virus Therapy, 22(11) MOLECULAR THERAPY 1949-59 (November 2014)

Guedan et al., GALV expression enhances the therapeutic efficacy of an oncolytic adenovirus by inducing cell fusion and enhancing virus distribution, 19 GENE THERAPY 1048-57 (2012)

Fu et al., Expression of a Fusogenic Membrane Glycoprotein by an Oncolytic Herpes Simplex Virus Potentiates the Viral Antitumor Effect, 7(6) MOLECULAR THERAPY 748-754 (June 2003)

Nakamori et al., Potent Antitumor Activity After Systemic Delivery of a Doubly Fusogenic Oncolytic Herpes Simplex Virus Against Metastatic Prostate Cancer, 60 THE PROSTATE 53-60 (2004)

Ebert et al., Syncytia Induction Enhances the Oncolytic Potential of Vesicular Stomatitis Virus in Virotherapy for Cancer, 64 CANCER RESEARCH 3265-3270 (May 2004)

Gomez-Trevino et al., Effects of adenovirus-mediated SV5 fusogenic glycoprotein expression on tumor cells, 5 J. GENE MED. (2003) 483-492

Sharp and Li, The codon adaptation index - a measure of directional synonymous codon usage bias, and its potential applications, 15(3) NUCLEIC ACIDS RESEARCH 1281-95 (1987)

Wennier et al., Bugs and Drugs: Oncolytic Virotherapy in Combination with Chemotherapy, 13(9) CURR. PHARM. BIOTECHNOL. 1817-33 (July 2012)

Le Boeuf et al., Synergistic Interaction Between Oncolytic Viruses Augments Tumor Killing, 18(5) MOLECULAR THERAPY 888-895 (May 2010)

Rojas et al., Defining Effective Combinations of Immune Checkpoint Blockade and Oncolytic Virotherapy, 21(24) CLIN. CANCER RES. 5543-51 (December 2015)

Ishihara et al., Systemic CD8+ T Cell-Mediated Tumoricidal Effects by Intratumoral Treatment of Oncolytic Herpes Simplex Virus with the Agonistic Monoclonal Antibody for Murine Glucocorticoid-Induced Tumor Necrosis Factor Receptor (August 2014)

John et al., Oncolytic Virus and Anti4-1BB Combination Therapy Elicits Strong Antitumor Immunity against Established Cancer, 72(7) CANCER RESEARCH 1651-60 (April 2012)

Deguchi et al., Combination of the Tumor Angiogenesis Inhibitor Bevacizumab and Intratumoral Oncolytic Herpes Virus Injections as a Treatment Strategy for Human Gastric Cancers, 59(118) HEPATOGASTROENTEROLOGY 1844-50 (September 2012)

Tan et al., Combination therapy of oncolytic herpes simplex virus HF10 and bevacizumab against experimental model of human breast carcinoma xenograft, 136 INT. J. CANCER 1718-30 (2015)

Fukuhara et al., Triple Gene-Deleted Oncolytic Herpes Simplex Virus Vector Double-Armed with Interleukin 18 and Soluble B7-1 Constructed by Bacterial Artificial Chromosome-Mediated System, 65(23) CANCER RES. 10663-68 (December 2005)

Lee et al., Enhanced Antitumor Effect of Oncolytic Adenovirus Expressing Interleukin-12 and B7-1in an Immunocompetent Murine Model, 12(19) CLIN. CANCER RES. 5859-68 (October 2006)

Carter et al., Identification of an overprinting gene in Merkel cell polyomavirus provides evolutionary insight into the birth of viral genes, 110(31) PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES 12744-49 (July 2013)

Published International Patent Application WO 2006/048749

U.S. Patent No. 9,487,581

Danthinne and Imperiale, Production of first generation adenovirus vectors: a review, 7 GENE THERAPY 1707-14 (2000)

Msaouel et al., Attenuated oncolytic Measles Virus strains as cancer therapeutics, 13(9) CURR. PHARM. BIOTECHNOL. 1732-41 (July 1, 2012)

McDonald et al., A measles virus vaccine strain derivative as a novel oncolytic agent against breast cancer, 99 BREAST CANCER RESEARCH AND TREATMENT 177-184 (2006)

Blechacz et al., Engineered Measles Virus as a Novel Oncolytic Viral Therapy System for Hepatocellular Carcinoma, 44(6) HEPATOLOGY 1465-77 (December 2006)

Kaufmann et al., Chemovirotherapy of Malignant Melanoma with a Targeted and Armed Oncolytic Measles Virus, 133 JOURNAL OF INVESTIGATIVE DERMATOLOGY 1034-42 (2013)

Jacobs et al., Vaccinia Virus Vaccines: Past, Present and Future, 84(1) ANTIVIRAL RES. 1-13 (October 2009)

Senzer et al., Phase II Clinical Trial of a Granulocyte-Macrophage Colony-Stimulating Factor-Encoding, Second-Generation Oncolytic Herpesvirus in Patients With Unresectable Metastatic Melanoma, 27(34) JOURNAL OF CLINICAL ONCOLOGY 5763-71 (December 1, 2009)

Kelly and Russell, History of Oncolytic Viruses: Genesis to Genetic Engineering, 15(4) MOLECULAR THERAPY 651-659 (April 2007)

Sinkovics and Horvath, Natural and genetically engineered viral agents for oncolysis and gene therapy of human cancers, 56 ARCH. IMMUNOL. THER. EXP. 3-59 (2008)

Study Details for Clinical Trial NCT02620423 Study of Pembrolizumab with REOLYSIN and Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma, last updated September 13, 2018, available at: https://clinicaltrials.gov/ct2/show/NCT02620423

Ahmed et al., Intratumoral expression of a fusogenic membrane glycoprotein enhances the efficacy of replicating adenovirus therapy, 10 GENE THERAPY 1663-71 (2003)

Study Details for Clinical Trial NCT02272855 A Study of Combination Treatment With HF10 and Ipilimumab in Patients With Unresectable or Metastatic Melanoma, last updated September 26, 2018, available at: https://clinicaltrials.gov/ct2/show/NCT02272855

Simpson et al., Combination of a Fusogenic Glycoprotein, Prodrug Activation, and Oncolytic Herpes Simplex Virus for Enhanced Local Tumor Control, 66(9) CANCER RES. 4835-42 (May 1, 2006)

Pentcheva-Hoang et al., B7-1 and B7-2 Selectively Recruit CTLA-4 and CD28 to the Immunological Synapse, 21 IMMUNITY 401-413 (September 2004)

Choi et al., Polymeric oncolytic adenovirus for cancer gene therapy, 219 JOURNAL OF CONTROLLED RELEASE 181-191 (2015)

Croyle et al., PEGylation of a Vesicular Stomatitis Virus G Pseudotyped Lentivirus Vector Prevents Inactivation in Serum, 78(2) JOURNAL OF VIROLOGY 912-921 (January 2004)

Tesfay et al., PEGylation of Vesicular Stomatitis Virus Extends Virus Persistence in Blood Circulation of Passively Immunized Mice, 87(7) JOURNAL OF VIROLOGY 3752-59 (April 2013)

Lipson and Drake, Ipilimumab: An Anti-CTLA-4 Antibody for Metastatic Melanoma, 17(22) CLIN. CANCER RES. 6958-62 (November 2011)

Ribas, Clinical Development of the Anti-CTLA-4 Antibody Tremelimumab, 37(5) SEMINARS IN ONCOLOGY 450-454 (October 2010)

Output from Biocompare search for CTLA-4 Antibodies (performed Nov. 24, 2021), available at https://www.biocompare.com/Search-Antibodies/?search=CTLA-4&said=0

Output from Antibodypedia search for CTLA-4 Antibodies (performed Nov. 24, 2021), available at https://www.antibodypedia.com/gene/19961/CTLA4

Output from antibodies-online.com search for CTLA-4 Antibodies (performed Nov. 24, 2021), available at https://www.antibodies-online.com/search.php#5qk9

Smith et al., Studies on the Use of Viruses in the Treatment of Carcinoma of the Cervix, 9(6) CANCER 1211-18 (November-December 1956)

Asada, Treatment of Human Cancer with Mumps Virus, 34(6) CANCER 1907-28 (December 1974)

International Search Report for International Patent Application No. PCT/FI2009/051025

International Search Report for International Patent Application No. PCT/EP2015/066263

Kleinpeter et al., Vectorization in an oncolytic vaccinia virus of an antibody, a Fab and a scFv against programmed cell death -1 (PD-1) allows their intratumoral delivery and an improved tumor-growth inhibition, 5(10) ONCOIMMUNOLOGY e1220467 (2016)

Documents filed on July 9, 2018 in U.S. Patent Application Serial No. 16/068,830, including original application, preliminary amendment, application data sheet, search report, and transmittal form

Ishikawa et al., STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity, 461 NATURE 788-792 (October 8, 2009)